治験レーダーAI | ||
|---|---|---|
治験 NCT06539624（対象：ファブリー病）は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
フィルター基準に一致する試験が1件見つかりました
タイル表示
Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease 12
治験（臨床試験）の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします！「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT06539624 は 介入研究 臨床試験 で、ファブリー病 に関するものです。現在は 募集中 で、2024年10月16日 から開始しています。12 名の参加者 の募集が計画されています。この試験は The Children's Hospital of Zhejiang University School of Medicine によって主導され、2027年4月9日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2026年2月27日 です。
概要
Objective: To explore the safety and tolerability of different doses of EXG110 with Fabre disease
詳細説明
An open-label, multicenter, single-arm, non-randomized, dose-escalation, and recommended dose-extension clinical design was used to evaluate the safety and efficacy of a single intravenous administration of different doses of EXG110 in patients
公式タイトル
A Multicenter, Non-randomized, Open-label, Dose-finding Study to Evaluate the Safety and Preliminary Efficacy of Gene Therapy With EXG110 in Subjects With Fabry Disease
疾患名
ファブリー病その他の研究識別子
- EXG110-011
主目的
治療
割付方法
非無作為化
介入モデル
逐次割当
盲検化
なし（非盲検）
群（アーム）／介入
| 参加グループ/群 | 介入/治療法 |
|---|---|
実験的Dose escalation-Cohort 1 Genetic : EXG110 | EXG110 injection EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion. |
実験的Dose escalation-Cohort 2 Genetic : EXG110 | EXG110 injection EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion. |
実験的Dose escalation-Cohort 3 Genetic : EXG110 | EXG110 injection EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion. |
実験的Dose escalation-Cohort 4 Genetic : EXG110 | EXG110 injection EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion. |
主要評価項目
副次評価項目
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Incidence and severity of adverse events | Safety and tolerability of EXG110 following a single IV dose, as assessed by incidence and severity of adverse events, serious adverse events and dose limiting toxicities, including clinically significant changes from baseline to scheduled time points in safety parameters | 52 weeks following EXG110 administration |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
eGFR change from baseline in mL/min/(1.73m^2); | eGFR change from baseline in mL/min/(1.73m\^2) | 52 weeks following EXG110 administration |
NYHA cardiac function grade changed from baseline; | NYHA cardiac function grade changed from baseline; | 52 weeks following EXG110 administration |
Changed from baseline: region and area in mm^2 of skin angiokeratoma The number of Gb3 deposition in skin biopsy under the microscope | Changed from baseline: region and area in mm\^2 of skin angiokeratoma The number of Gb3 deposition in skin biopsy under the microscope | 52 weeks following EXG110 administration |
Change from baseline in serum AGA activity | Change from baseline in serum AGA activity | 52 weeks following EXG110 administration |
Change from baseline serum lysoGb3 | Change from baseline serum lysoGb3 | 52 weeks following EXG110 administration |
参加アシスタント
適格基準
対象年齢
小児, 成人, 高齢者
試験の最低年齢
7 Years
対象性別
全て
- At the time of signing the informed consent, age ≥7, male or female
- Clinical symptoms (at least one Fabry disease related symptom) and genetic diagnosis of Fabry disease,
- Prior or no prior ERT treatment
- Have renal or cardiac involvement (adults only)
- All subjects of reproductive age voluntarily took effective contraception and prohibited sperm donation from entering the screening period until 52 weeks after dosing (main study period)
- The subjects voluntarily participate and are fully informed, fully understand the research, can comply with the requirements of the research protocol, and are willing to complete the research as planned, and voluntarily provide biological samples for testing according to the requirements of the protocol
- Screening period laboratory test results: a) aspartate aminotransferase or alanine aminotransferase > 1.5× upper limit of normal (ULN);b) Total bilirubin > 1.5× upper limit of normal (ULN);c) Alkaline phosphatase > 2× upper limit of normal (ULN);d) Albumin < lower limit of normal (LLN)
- There was a clinically significant increase in AFP during the screening period
- Serum virology test: a) Hepatitis B: Hepatitis B virus surface antigen (HBsAg) positive, and hepatitis B virus-deoxyribonucleic acid (HBV-DNA) higher than the upper limit of normal detection;b) Hepatitis C: if the hepatitis C virus (HCV) antibody is positive, and the hepatitis C virus-ribonucleic acid (HCV-RNA) is higher than the upper limit of normal test value;c) Syphilis: positive for syphilis screening (Tp-Ab) and positive for syphile-specific antibodies;d) HIV: Known human immunodeficiency virus (HIV) positive history or HIV screening positive
- AVT917 (>1:50), anti-AGA antibody positive(>1:2560)
- C3 lower than the normal range, C5b-9 higher than the normal range, anti-AVT917 IgM positive
- Current or have a history of serious cardiovascular disease and surgical history
- Current underlying liver disease or history of liver disease, as assessed by the investigator, that may affect the safety assessment of the drug
- Renal disease in adult and the slope of kidney >5 mL/min/1.73m²/year
- Subjects with poorly controlled diabetes after drug treatment (e.g., HbA1c≥8%);
- Acute/chronic infection or other chronic disease that the investigator determines will increase the risk of participants participating in the study
- Patients with a history of malignant tumor or currently suffering from any malignant tumor (except for the following tumor diseases: skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, skin squamous cell carcinoma has been controlled after treatment);
- Have malignancy cancer
- Patients with active autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, immune vasculitis, inflammatory bowel disease, etc.);
- known history of allergy to the components of the investigational products
- Patients with a history of drug use or drug abuse or alcoholism
- Use of systemic (intravenous or oral) immunomodulators within the past 6 months or currently
- Initiation of treatment with blood pressure lowering drugs that affect proteinuria levels (such as angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or angiotensin-receptor/enkephalin inhibitors) within 4 weeks prior to screening, or changes in the therapeutic dose of these drugs within 4 weeks prior to screening;
- Has received, or is currently receiving, a clinical trial of another investigational drug/medical device or treatment (other than vitamins and minerals) within 3 months prior to signing the informed consent (or within 5 half-lives of the investigational drug, whichever is longer)
- Previous treatment with gene therapy products
- Those who had received live attenuated vaccine/vaccine within 12 weeks prior to screening or planned to receive it during the study
- Other clinical conditions that the investigators felt needed to be ruled out
The Children's Hospital of Zhejiang University School of Medicine責任者
Mao Jianhua, 主任研究者, Vice President of the hospital, The Children's Hospital of Zhejiang University School of Medicine
試験中央連絡先
連絡先: Jianhua Mao, PhD, 13516819071, [email protected]
2 1カ国の場所
Shanghai Municipality
Shanghai Children's Medical Center, Shanghai, Shanghai Municipality, China
Lei Yin, PhD, 連絡先, 13641673203, [email protected]
Lei Yin, PhD, 主任研究者
募集中
Zhejiang
Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Mao Jianhua, MD, 連絡先, 13616819071, [email protected]
募集中